 Connection
Lucas Zarling to Humans
This is a "connection" page, showing publications Lucas Zarling has written about Humans.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.085 |
|
|
|
-
Zarling LC, Stevenson PA, Soma LA, Martino CH, Percival MM, Halpern AB, Ghiuzeli CM, Becker PS, Oehler VG, Cooper JP, Orozco JJ, Hendrie PC, Walter RB, Estey EH, Cassaday RD. Hyper-CVAD versus dose-adjusted EPOCH as initial treatment for adults with acute lymphoblastic leukemia. Eur J Haematol. 2023 Dec; 111(6):863-871.
Score: 0.022
-
Zarling LC, Othus M, Sandmaier BM, Milano F, Schoch G, Davis C, Bleakley M, Deeg HJ, Appelbaum FR, Storb R, Walter RB. Utility of the?Treatment-Related Mortality (TRM)?score to predict outcomes of adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation. Leukemia. 2022 06; 36(6):1563-1574.
Score: 0.020
-
Zarling L, Emamekhoo H, Bhutani G, Ziemlewicz T, Matkowskyj KA, Kyriakopoulos CE. Polycystic Liver Disease in a Patient With Metastatic Renal Cell Carcinoma: A Case Report. Anticancer Res. 2020 Mar; 40(3):1527-1534.
Score: 0.017
-
Kratz JD, Rehman S, Johnson KA, Gillette AA, Sunil A, Favreau PF, Pasch CA, Miller D, Zarling LC, Yeung AH, Clipson L, Anderson SJ, Steimle AK, Sprackling CM, Lemmon KK, Abbott DE, Burkard ME, Bassetti MF, Eickhoff JC, Foley EF, Heise CP, Kimple RJ, Lawson EH, LoConte NK, Lubner SJ, Mulkerin DL, Matkowskyj KA, Sanger CB, Uboha NV, Mcilwain SJ, Ong IM, Carchman EH, Skala MC, Deming DA. Subclonal response heterogeneity to define cancer organoid therapeutic sensitivity. Sci Rep. 2025 Apr 09; 15(1):12072.
Score: 0.006
-
Cassaday RD, Zarling LC, Garcia KA, Sala-Torra O, Stevenson PA, Martino CH, Liu YJ, Fang M, Percival MM, Halpern AB, Becker PS, Oehler VG, Shustov AR, Cooper JP, Orozco JJ, Hendrie PC, Walter RB, Radich JP, Soma LA, Estey EH. Phase II study of dose-adjusted EPOCH as initial therapy for adults with high-risk acute lymphoblastic leukemia. Leuk Lymphoma. 2023 05; 64(5):927-937.
Score: 0.005
-
Rodr?guez-Arbol? E, Othus M, Orvain C, Zarling LC, Sandmaier BM, Milano F, Schoch G, Davis C, Deeg HJ, Appelbaum FR, Storb R, Walter RB. Contribution of measurable residual disease status to prediction accuracy of relapse and survival in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation. Haematologica. 2023 01 01; 108(1):273-277.
Score: 0.005
-
Paras G, Morsink LM, Othus M, Milano F, Sandmaier BM, Zarling LC, Palmieri R, Schoch G, Davis C, Bleakley M, Flowers MED, Deeg HJ, Appelbaum FR, Storb R, Walter RB. Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML. Blood. 2022 03 17; 139(11):1694-1706.
Score: 0.005
-
Wesener DA, Wangkanont K, McBride R, Song X, Kraft MB, Hodges HL, Zarling LC, Splain RA, Smith DF, Cummings RD, Paulson JC, Forest KT, Kiessling LL. Recognition of microbial glycans by human intelectin-1. Nat Struct Mol Biol. 2015 Aug; 22(8):603-10.
Score: 0.003
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|